55 results
Keyword Neupro - Cerotti Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Neupro
rotigotine, Restless Legs Syndrome; Parkinson Disease
Date of authorisation: 15/02/2006, Revision: 31, Authorised, Last updated: 10/12/2021Neupro Nervous System Diseases Sleep … part of the EPAR). What is Neupro? Neupro is a range of transdermal … rotigotine over 24 hours. What is Neupro used for Neupro is used to treat the symptoms … -
List item
Press release: EMEA recommends changes in the storage conditions for Neupro (rotigotine)
Last updated: 04/06/2008the storage conditions for Neupro (rotigotine … the storage conditions for Neupro (rotigotine … the storage conditions for Neupro (rotigotine) The European … -
List item
Press release: European Medicines Agency recommends lifting of supply and treatment restrictions for Neupro
CHMP, Last updated: 29/05/2009treatment restrictions for Neupro … treatment restrictions for Neupro … treatment restrictions for Neupro The European Medicines … -
List item
Withdrawn application: Rotigotine Mylan
rotigotine, date of withdrawal: 22/12/2017, Initial authorisation, Last updated: 11/07/2018the European Union called Neupro. What was Rotigotine Mylan … with the reference medicine, Neupro, and did not need to be repeated … the European Union called Neupro. For more information on generic … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,21-24 April 2008
CHMP, Last updated: 29/04/2008with parathyroid carcinoma. Neupro (rotigotine), from SchwarzPharma … severe restless legs syndrome. Neupro is currently indicated for … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 April 2011
CHMP, Last updated: 15/04/2011of the authorised medicine Neupro. … of the authorised medicine Neupro. Positive opinion for generic … -
List item
Human medicine European public assessment report (EPAR): Leganto
rotigotine, Restless Legs Syndrome; Parkinson Disease
Date of authorisation: 16/06/2011, Revision: 19, Withdrawn, Last updated: 18/02/2022Leganto was a duplicate of Neupro, which is marketed in several … This medicine is the same as Neupro, which is already authorised … EU). The company that makes Neupro has agreed that its scientific … -
List item
Human medicine European public assessment report (EPAR): Upstaza
Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022,
, 
, 
, Revision: 2, Authorised, Last updated: 30/09/2022
-
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 August 2022
Written procedure, from 16/08/2022 to 19/08/2022, Last updated: 04/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 23/11/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 23/11/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/02/2021 to 25/02/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 04/03/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 April 2018
European Medicines Agency, London, UK, from 23/04/2018 to 26/04/2018, Last updated: 08/06/2018 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 December 2013
European Medicines Agency, London, UK, from 02/12/2013 to 05/12/2013, Last updated: 02/07/2012 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use, 26-29 May 2009
CHMP, Last updated: 29/05/2009treatment restrictions for Neupro The Committee recommended … treatment restrictions for Neupro (rotigotine transdermal … Commission, the ban on prescribing Neupro to patients not yet taking … -
List item
Article 5(3) opinions
Last updated: 10/01/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 March 2013
European Medicines Agency, London, UK, from 04/03/2013 to 07/03/2013, Last updated: 02/06/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 September 2013
European Medicines Agency, London, UK, from 02/09/2013 to 05/09/2013, Last updated: 02/07/2012 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-28 June 2018
European Medicines Agency, London, UK, from 25/06/2018 to 28/06/2018, Last updated: 06/01/2014 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 29/11/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 9-12 October 2017
European Medicines Agency, London, UK, from 09/10/2017 to 12/10/2017, Last updated: 06/01/2014